Page last updated: 2024-08-23

mefloquine and Breast Neoplasms

mefloquine has been researched along with Breast Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Petasis, NA; Schönthal, AH; Sharma, N; Thomas, S1

Reviews

1 review(s) available for mefloquine and Breast Neoplasms

ArticleYear
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022

Other Studies

1 other study(ies) available for mefloquine and Breast Neoplasms

ArticleYear
Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent.
    Cancer letters, 2012, Dec-30, Volume: 326, Issue:2

    Topics: Antimalarials; Autophagy; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mefloquine; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ubiquitination

2012